E-LIB Suche - Ergebnisse für: Brandt-Jürgens, Jan

1

Efficacy and NSAID-sparing effect of secukinumab 150 mg in ..:

Kiltz, Uta ; Baraliakos, Xenofon ; Brandt-Jürgens, Jan...
Therapeutic Advances in Musculoskeletal Disease. 16 (2024) - p. , 2024

Link: https://doi.org/10.1177/..

2

Characteristics and outcomes of SARS-CoV-2 breakthrough inf..:

Hasseli, Rebecca ; Richter, Jutta G. ; Hoyer, Bimba Franziska...
RMD Open. 9 (2023) 2 - p. e002998 , 2023

Link: https://doi.org/10.1136/..

3

P174 Psoriatic arthritis patients in the UK have a lower qu..:

Coyle, Conor ; Watson, Lily ; Brooke, Melanie...
Rheumatology. 62 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

4

Validation of the Simplified Disease Activity Index (SDAI) ..:

Schally, Julia ; Brandt, Henning Christian ; Brandt-Jürgens, Jan...
Therapeutic Advances in Musculoskeletal Disease. 14 (2022) - p. 1759720X2211141 , 2022

Link: https://doi.org/10.1177/..

5

P186 Secukinumab effectiveness and safety in patients with ..:

Gaffney, Karl ; Gullick, Nicola ; Kiltz, Uta...
Rheumatology. 60 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

6

Secukinumab Use in Patients with Moderate to Severe Psorias..:

Kiltz, Uta ; Sfikakis, Petros P. ; Gaffney, Karl...
Advances in Therapy. 37 (2020) 6 - p. 2865-2883 , 2020

Link: https://doi.org/10.1007/..

7

Switching to Biosimilar SDZ-ADL in Patients with Moderate-t..:

Wiland, Piotr ; Jeka, Sławomir ; Dokoupilová, Eva...
BioDrugs. 34 (2020) 6 - p. 809-823 , 2020

Link: https://doi.org/10.1007/..

8

Differences in treatment response between female and male p..:

Koehm, Michaela ; Foldenauer, Ann C ; Rossmanith, Tanja...
https://freidok.uni-freiburg.de/data/242825. , 2023

Link: https://freidok.uni-frei..

9

Characteristics and outcomes of SARS-CoV-2 breakthrough inf..:

Hasseli, Rebecca ; Richter, Jutta G ; Hoyer, Bimba Franziska...
https://freidok.uni-freiburg.de/data/235773. , 2023

Link: https://freidok.uni-frei..

10

Entwicklung von Qualitätsstandards für Patient*innen mit ax..:

Kiltz, Uta ; Buschhorn-Milberger, Verena ; Albrecht, K...
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63765. , 2021

Link: http://publikationen.ub...

11

Secukinumab Use in Patients with Moderate to Severe Psorias..:

Kiltz, Uta ; Sfikakis, Petros P ; Gaffney, Karl...
boreal:229901. , 2020

Link: http://hdl.handle.net/20..

12

Secukinumab use in patients with moderate to severe psorias..:

Kiltz, Uta ; Sfikakis, Petros P ; Gaffney, Karl...
https://ueaeprints.uea.ac.uk/id/eprint/76592/1/Published_Version.pdf. , 2020

Link: https://ueaeprints.uea.a..

13

Secukinumab Use in Patients with Moderate to Severe Psorias..:

Kiltz, Uta ; Sfikakis, Petros P ; Gaffney, Karl...
boreal:229901. , 2020

Link: http://hdl.handle.net/20..

14

Entwicklung von Qualitätsstandards für Patient*innen mit ax..:

Kiltz, Uta (Prof. Dr. med.) ; Buschhorn-Milberger, Verena (Dr. med.) ; Albrecht, Katinka (Dr. med.)...
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/10053. , 2021

Link: https://hss-opus.ub.ruhr..

15

Characteristics and outcomes of SARS-CoV-2 breakthrough inf..:

Tobias Alexander ; Hendrik Schulze-Koops ; Ulf Müller-Ladner...
https://rmdopen.bmj.com/content/9/2/e002998.full. , 2023

Link: https://doi.org/10.1136/..